Current state and novel approaches of antiplatelet therapy

Area of Science:

• Pharmacology
• Hematology
• Cardiovascular Medicine

Background:

• Antiplatelet therapy is crucial for preventing athero/thrombotic disease and surgical thrombus formation.
• Clinical use faces challenges including patient resistance to standard doses and critical roles of platelet targets in hemostasis.
• A significant number of individuals experience either persistent thrombosis or life-threatening bleeding despite therapy.

Purpose of the Study:

• To review current antiplatelet therapies and their targets.
• To focus on novel approaches for antiplatelet therapy.
• To explore improved monitoring of platelet reactivity for better antithrombosis with reduced bleeding.

Main Methods:

• Literature review of existing antiplatelet strategies.
• Examination of current drug targets and their limitations.
• Discussion of emerging antiplatelet targets and monitoring techniques.

Main Results:

• Current antiplatelet drugs target specific pathways but leave a gap in managing thrombosis and bleeding risks.
• Primary platelet adhesion-signaling receptors, glycoprotein (GP)Ib-IX-V and GPVI, are key in thrombus formation under pathological shear and are not currently targeted.
• New therapeutic strategies and monitoring methods are needed to optimize antiplatelet treatment.

Conclusions:

• Optimizing antiplatelet therapy requires addressing current limitations in efficacy and safety.
• Targeting novel pathways, such as GP Ib-IX-V and GPVI, presents a promising avenue for improved antithrombotic effects.
• Enhanced monitoring of individual platelet reactivity is essential for personalized and effective antiplatelet treatment to minimize bleeding risks.